PET PET
  • My Account
  • Subscribe
Become a Friend Donate
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • My Account
  • Subscribe
  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements
PETBioNewsNewsProgesterone does not help women with recurrent miscarriages

BioNews

Progesterone does not help women with recurrent miscarriages

Published 14 September 2016 posted in News and appears in BioNews 830

Author

Rikita Patel

Image by Alan Handyside via the Wellcome Collection. Depicts a human egg soon after fertilisation, with the two parental pronuclei clearly visible.
CC0 1.0
Image by Alan Handyside via the Wellcome Collection. Depicts a human egg soon after fertilisation, with the two parental pronuclei clearly visible.

Progesterone supplementation in the first trimester of pregnancy does not improve outcomes for women with unexplained recurrent miscarriages, according to a large clinical trial...

Progesterone supplementation in the first trimester of pregnancy does not improve outcomes for women with unexplained recurrent miscarriages, according to a large clinical trial.

The PROMISE trial conducted in the UK and Netherlands included 826 women aged between 18–39 years with a history of recurrent miscarriages. Participants received either twice-daily vaginal preparations of 400 mg progesterone or placebo from shortly after conception up to the 12th week of pregnancy. Neither participants nor doctors knew which they were receiving.

During the study, almost two-thirds of participants gave birth at 24 weeks gestation or later. With a live birth rate of 65.8 percent and 63.3 percent in the progesterone therapy and placebo group, respectively, the researchers concluded that administration of progesterone does not significantly affect the rate of live births. This was true regardless of the women's age, ethnicity, medical history and pregnancy history.

Progesterone is produced naturally in early pregnancy by the corpus luteum in the ovary, and is essential to help achieve and maintain early pregnancy. For this reason, many studies have sought to evaluate the effectiveness of supplementation for reducing the risk of recurrent miscarriages.

After 60 years of uncertainty, the researchers say the PROMISE trial, which is published in the New England Journal of Medicine, should provide a conclusive answer.

Lead author, Professor Arri Coomarasamy, from the University of Birmingham, commented, 'We had hoped, like many people, that this research would confirm progesterone as an effective treatment. Though disappointing, it does address a question that has remained unanswered since progesterone was first proposed as a treatment back in 1953.'

Contrary to the results of this trial, previous findings from a Cochrane analysis of four small studies support the use of first-trimester progesterone therapy. However, these trials had 'substantive methodological limitations', the authors of the current study state.

Professor Coomarasamy said, 'Fortunately, there are a number of other positives that we can take from the trial as a whole.' For example, no statistical difference in adverse outcomes (such as congenital abnormalities) between the groups were reported. This is reassuring for women who take progesterone for fertility treatment purposes or those involved in other trials.

'It may well be that progesterone supplements have other uses, such as preventing miscarriage in women with early pregnancy bleeding, so it's not the end of the road,' Professor Coomarasamy added. 

Related Articles

Image by Alan Handyside via the Wellcome Collection. Depicts a human egg soon after fertilisation, with the two parental pronuclei clearly visible.
CC0 1.0
Image by Alan Handyside via the Wellcome Collection. Depicts a human egg soon after fertilisation, with the two parental pronuclei clearly visible.
News
25 May 2016 • 2 minutes read

Protein may help embryos stick to uterus

by Dr Jane Currie

Researchers have identified a protein that may help developing embryos stick to the uterus...

Image by Alan Handyside via the Wellcome Collection. Depicts a human egg soon after fertilisation, with the two parental pronuclei clearly visible.
CC0 1.0
Image by Alan Handyside via the Wellcome Collection. Depicts a human egg soon after fertilisation, with the two parental pronuclei clearly visible.
News
10 March 2016 • 2 minutes read

Lack of stem cells in womb linked to recurrent miscarriage

by Dr Lanay Griessner

Recurrent miscarriage could be caused by a lack of resident stem cells in the lining of the womb, according to a study...

Image by Alan Handyside via the Wellcome Collection. Depicts a human egg soon after fertilisation, with the two parental pronuclei clearly visible.
CC0 1.0
Image by Alan Handyside via the Wellcome Collection. Depicts a human egg soon after fertilisation, with the two parental pronuclei clearly visible.
Comment
9 November 2015 • 3 minutes read

Natural killer cells and fertility: unwarranted treatments flourish amid misinformation and poor regulation

by Dr Norman Shreeve

In recent years a range of treatments aimed at suppressing uterine natural killer activity have sprung up, but this has no scientific rationale and can have significant and dangerous side effects...

Image by Alan Handyside via the Wellcome Collection. Depicts a human egg soon after fertilisation, with the two parental pronuclei clearly visible.
CC0 1.0
Image by Alan Handyside via the Wellcome Collection. Depicts a human egg soon after fertilisation, with the two parental pronuclei clearly visible.
News
21 March 2013 • 2 minutes read

'Super-fertility' to blame for some recurrent miscarriages, study suggests

by John Brinsley

Women who repeatedly reject pregnancies may be 'too good' at carrying, research indicates...

Leave a Reply Cancel reply

You must be logged in to post a comment.

« Passive smoking linked to increase risk of infertility

Data-Label The UK's Leading Supplier Of Medical Labels & Asset Labels

RetiringDentist.co.uk The UK's Leading M&A Company.
easyfundraising
amazon

This month in BioNews

  • Popular
  • Recent
13 June 2022 • 2 minutes read

Drop in diversity of blood stem cells leads to old-age health issues

5 July 2022 • 1 minute read

No difference between fresh and frozen sperm for IUI

4 July 2022 • 2 minutes read

Shorter IVF protocol reduces risk of OHSS

4 July 2022 • 2 minutes read

USA scrambles to understand implications of Roe v Wade on fertility industry

4 July 2022 • 2 minutes read

Genetic and epigenetic causes of IVF embryo arrest discovered

4 July 2022 • 2 minutes read

Dutch donor-conceived people seek answers

Subscribe to BioNews and other PET updates for free.

Subscribe
  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856

Subscribe to BioNews and other PET updates for free.

Subscribe
PET PET

PET is an independent charity that improves choices for people affected by infertility and genetic conditions.

  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Navigation

  • About Us
  • Get Involved
  • Donate
  • BioNews
  • Events
  • Engagement
  • Jobs & Opportunities
  • Contact Us

BioNews

  • News
  • Comment
  • Reviews
  • Elsewhere
  • Topics
  • Glossary
  • Newsletters

Other

  • My Account
  • Subscribe

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856